个人简历

教育背景\r
2008.09 – 2012.01，复旦大学化学系，博士\r
2003.09 – 2006.06，湖北省化学研究院，硕士\r
1999.09 – 2003.06，武汉工程大学化工与制药学院，学士\r
\r
工作履历\r
2017.11-2018.10 University of Virginia, 访问学\r
2014.10 – 2015.10，University of Virginia, 博士后\r
2012.02 – 目前，武汉工程大学化工与制药学院，历任讲师/副教授/楚天学子特聘教授\r
2006.07 – 2008.08 湖北省化学研究院，实习研究员

研究领域

"""""（1）药物化学（抗HIV和抗肿瘤）：抗HIV-1和抗肿瘤新化合物的分子设计、合成、生物活性和构效关系研究；\r
（2）手性化学（手性分子识别、不对称合成与催化）: a. 手性化合物的荧光识别探针设计、合成及其在ee值快速分析和高通量筛选中的应用；b. 手性药物及其中间体的不对称合成与催化及其工业化；\r
（3）药物合成工艺&绿色化工过程：药物的合成工艺开发和绿色化工过程研究，旨在开发低成本和绿色环保的合成新工艺。"

近期论文

Gu SX, Lu HH, Liu GY, et al. Advances in diarylpyrimidines and related analogues as HIV-1 nonnucleoside reverse transcriptase inhibitors [J]. Eur. J. Med. Chem. 2018, 158: 371-392. (Review, first author, corresponding author) \r
\r
Liu G, Wan Y, Wang W, et al. Docking-based 3D-QSAR and pharmacophore studies on diarylpyrimidines as non-nucleoside inhibitors of HIV-1 reverse transcriptase [J]. Mol. Divers. 2018. 10.1007/s11030-018-9860-1. (corresponding author)\r
\r
Liu G, Wang W, Wan Y, et al. Application of 3D-QSAR, Pharmacophore, and Molecular Docking in the Molecular Design of Diarylpyrimidine Derivatives as HIV-1 Nonnucleoside Reverse Transcriptase Inhibitors [J]. Int. J. Mol. Sci. 2018, 19(5), 1436. (corresponding author)\r
\r
Lu HH, Xue P, Zhu YY, et al. Structural modifications of diarylpyrimidines (DAPYs) as HIV-1 NNRTIs: synthesis, anti-HIV activities and SAR. Bioorg. Med. Chem. 2017, 25 (8), 2491-2497.(corresponding author) \r
\r
Xue P, Lu HH, Zhu YY, et al. Design and synthesis of hybrids of diarylpyrimidines and diketo acids as HIV-1 inhibitors. Bioorg. Med. Chem. Lett. 2017, 27 (8), 1640-1643. (corresponding author) \r
\r
Gu SX, Xue P, Ju XL, et al. Advances in rationally designed dual inhibitors of HIV-1 reverse transcriptase and integrase. Bioorg. Med. Chem. 2016, 24 (21), 5007-5016. (Review, first author, corresponding author) \r
\r
Gu SX, Huang WC, Wu XD, et al. Simple and Efficient One-Step Synthesis of a Highly Enantioselective Catalyst 3,3′-Di(pyrrolidinylmethyl)-H8BINOL. Synth. Commun. 2015, 45 (13), 1541-1545. (first author)\r
\r
Gu SX, Qiao H, Zhu YY, et al. A novel family of diarylpyrimidines (DAPYs) featuring a diatomic linker: Design, synthesis and anti-HIV activities. Bioorg. Med. Chem. 2015, 23 (20), 6587-6593. (first author, corresponding author) \r
\r
Gu SX, Zhu YY, Chen FE, et al. Structural modification of diarylpyrimidine derivatives as HIV-1 reverse transcriptase inhibitors. Med. Chem. Res., 2015, 24, 220-225. (first author, corresponding author) \r
\r
Gu SX, Du JW, Ju XL, et al. A scalable one-pot process for the synthesis of florfenicol phosphodiester. Org. Process Res. Dev., 2014, 18, 52-554. (first author) \r
\r
Gu SX, Li ZM, Ma XD, et al. Chiral resolution, absolute configuration assignment and biological activity of racemic diarylpyrimidine CH(OH)-DAPY as potent nonnucleoside HIV-1 reverse transcriptase inhibitors. Eur. J. Med. Chem. 2012, 53, 229-234. (first author) \r
\r
Gu SX, Yang SQ, He QQ, et al. Design, synthesis and biological evaluation of cycloalkyl arylpyrimidines (CAPYs) as HIV-1 NNRTIs. Bioorg. Med. Chem. 2011, 19 (23), 7093-7099. (first author) \r
\r
Gu SX; He QQ; Yang SQ, et al. Synthesis and structure-activity relationship of novel diarylpyrimidines with hydroxymethyl linker (CH(OH)-DAPYs) as HIV-1 NNRTIs. Bioorg. Med. Chem. 2011, 19 (17), 5117-5124. (first author) \r
\r
Gu SX, Zhang X, He QQ, et al. Synthesis and biological evaluation of naphthyl phenyl ethers (NPEs) as novel nonnucleoside HIV-1 reverse transcriptase inhibitors. Bioorg. Med. Chem. 2011, 19 (14), 4220-4226. (first author)